Wanting to learn more about medicine access equity? The He Ako Hiringa website is your gateway to education, resources, tools and data.
Late last year, PHARMAC announced the SGLT2 inhibitor empagliflozin (Jardiance®) and empagliflozin with metformin (Jardiamet®) will be funded for the treatment of type 2 diabetes with a novel new Special Authority criteria.
Find out all you need to know about the Special Authority criteria.
EPiC Diabetes dashboard is launching in February 2021. If you are a GP practicing in New Zealand and would like to use a data analytics tool that can help you assess your prescribing with respect to type-2 diabetes, your peers, demographics, current and stepped treatments then sign up now. To be a early user, click on Join link above for an invite to our launch activities or learn more by clicking on the EPiC Dashboard link above.
The call for equity in healthcare is not new but it is louder than it has ever been before. This article shares the experiences of primary care clinicians around the country as they work to improve medicine access equity for patients. This reading is part of a PSNZ accredited ELearning (Group 2) course for pharmacists and is suitable for professional development for nurses and general practitioners.
Subscribe to our newsletter to remain up to date with all our content and new features.